All eyes on Biogen’s experimental Alzheimer’s drug as FDA deadline nears

Less than a week out from the deadline for the U.S. Food and Drug Administration’s decision on Biogen Inc.’s much-anticipated Alzheimer’s drug, the biotech world is holding its breath for what has been described as a make-or-break product for the Cambridge company.